Relevant bibliographies by topics / Bsam yas

Contents

  1. Journal articles
  2. Books
  3. Conference papers

Academic literature on the topic 'Bsam yas'

Author: Grafiati
Published: 4 June 2025
Last updated: 23 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bsam yas.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bsam yas"

1

Tanaka, Kimiaki. "Wallpaintings and Mandalas at bSam-yas." JOURNAL OF INDIAN AND BUDDHIST STUDIES (INDOGAKU BUKKYOGAKU KENKYU) 35, no. 1 (1986): 472–69. http://dx.doi.org/10.4259/ibk.35.472.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chayet, Anne. "Le monastère de bSam-yas : sources architecturales." Arts asiatiques 43, no. 1 (1988): 19–29. http://dx.doi.org/10.3406/arasi.1988.1232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

BUFFETRILLE, K. "La restauration du monastère de bSam yas." Journal Asiatique 277, no. 3 (1989): 363–411. http://dx.doi.org/10.2143/ja.277.3.2011505.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mémet, Sébastien. "Le monastère de bSam-yas : essai de restitution." Arts asiatiques 43, no. 1 (1988): 30–32. http://dx.doi.org/10.3406/arasi.1988.1233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

MAKIDONO, Tomoko. "dGe rtse Mahapandita's Understanding of the bSam yas Debate." Journal of Indian and Buddhist Studies (Indogaku Bukkyogaku Kenkyu) 64, no. 1 (2015): 487–82. http://dx.doi.org/10.4259/ibk.64.1_487.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kellner, Birgit. "Where Did Kamalaśīla Compose His Works, and Does It Even Matter? Reflections on the Activities of Indian Scholars in Imperial Tibet." Asiatische Studien - Études Asiatiques 77, no. 1 (2023): 245–75. http://dx.doi.org/10.1515/asia-2023-0003.

Full text
Abstract:
Abstract This article reflects on the activities of the Indian Buddhist scholar-monk Kamalaśīla (c. 740–795) in imperial Tibet. Following accounts offered by Tibetan historians of later periods, these activities have so far been understood as more or less limited to Kamalaśīla’s victorious participation in the historically momentous “Great Debate” at Bsam yas monastery against the Chinese Chan master Heshang Moheyan. This article suggests that he also composed altogether seven of his works – and possibly more – while residing in Tibet, and sketches aspects of his intellectual profile on this basis. While remaining focused on Kamalaśīla, the article also raises wider-ranging questions regarding the activities of Indian Buddhist scholars in imperial Tibet against the backdrop of interconnected histories across South, Central and East Asia.
APA, Harvard, Vancouver, ISO, and other styles
7

Cho, Joon Ho. "Sudden and Gradual Enlightenment of the Bsam yas Debate and Buddha-recollection of Master Cheonghwa." Korean Institute for Buddhist Studies 53 (August 31, 2020): 75–108. http://dx.doi.org/10.34275/kibs.2020.53.075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Laish, Eran. "The Embodiments of View: Simultaneous and Gradual Approaches in the Contemplative Typology of the Great Perfection." SMARATUNGGA: JURNAL OF EDUCATION AND BUDDHIST STUDIES 3, no. 2 (2023): 73–90. http://dx.doi.org/10.53417/sjebs.v3i2.111.

Full text
Abstract:
The assertion of a state which is unconditioned and beyond temporal change creates unavoidable tensions for any Buddhist account that concerns the shift from worldly experience to a liberated one. The presence of such tensions can be found in the controversy between simultaneous (cig char; yugapad) and gradual (rim gyis; krameṇa) conceptions of the contemplative path and the state of liberation itself. This controversy found its early Tibetan expression in the so-called bSam yas debate, in which representative figures of both approaches argued about basic contemplative and soteriological issues. Later on, Klong chen pa, the renowned 14th century Tibetan teacher, explicated several contemplative typologies that included elements from both approaches. This research belongs to qualitative research using two interpretative perspectives, namely the Pragmatic attitude that focuses on the actual results of the scheme and the Transcendental point of view. The results showed that by examining the typologies and their presuppositions it becomes clear how the efficacy of each approach is closely related to individual capacities of practitioners. As such, the tension between simultaneous and gradual models is revealed as deeply contextual and not binary.
APA, Harvard, Vancouver, ISO, and other styles
9

Yan, Hong, Luyao Bao, Chenglong Liu, et al. "Abstract LB368: A first-in-class CTLA-4×TIGIT BsAb selectively targets tumor-associated Treg cells to improve the safety profile of CTLA-4 targeting therapy." Cancer Research 85, no. 8_Supplement_2 (2025): LB368. https://doi.org/10.1158/1538-7445.am2025-lb368.

Full text
Abstract:
Abstract Background: Ipilimumab, an immune-checkpoint inhibitor, has demonstrated clinical benefits but is also associated with adverse events due to its effects on peripheral regulatory T cells (Tregs). Thus, selective targeting tumor-associated Tregs could improve the safety profile of ipilimumab. Based on this hypothesis, we developed a CTLA-4×TIGIT bispecific antibody (BsAb). By targeting CTLA-4 and TIGIT, it could selectively engage tumor-associated Tregs that co-express both markers, while minimizing its impact on peripheral Tregs, thereby reducing the toxicity associated with ipilimumab. Method: Bioinformatics was applied to analyze the expression profile of CTLA-4 and TIGIT on immune cells including Tregs derived from human peripheral blood mononuclear cells and tumor infiltrating lymphocytes. In vitro, we established CHO-K1-CTLA4 cells representing peripheral Tregs and CHO-K1-CTLA-4/TIGIT cells representing tumor-associated Tregs. CTLA-4/CD80 blockage and ADCC activity of CTLA-4×TIGIT BsAb were determined on these cells. Functionally, we evaluated T cell activation with CTLA-4×TIGIT BsAb treatment. ADCC activity of BsAb towards ex vivo expanded Tregs was also determined. In vivo, the MC38 syngeneic model in hCTLA-4/hTIGIT C57BL/6 mice was applied to validate the anti-tumor activity of the BsAb. The safety profile was evaluated in cynomolgus monkeys through a 4-week Good Laboratory Practice (GLP) toxicity study. Results: Single-cell sequencing analysis revealed the selective co-expression of CTLA-4 and TIGIT on tumor-associated Tregs compared to peripheral Tregs. CTLA-4×TIGIT BsAb was designed with one arm targeting CTLA-4 and another arm targeting TIGIT. Compared to the parental CTLA-4 antibody, the monovalent binding to CTLA-4 reduced the binding and blocking activity in CHO-K-1-CTLA4 cells. But due to its co-targeting to CTLA-4 and TIGIT, CTLA-4×TIGIT BsAb exerted good binding avidity and CTLA-4/CD80 blockage activity in CHO-K1-CTLA-4/TIGIT cells. Moreover, it exhibited potent ADCC activity towards CHO-K1-CTLA-4/TIGIT cells and ex vivo expanded Tregs. In the MC38 syngeneic model, CTLA-4×TIGIT BsAb exhibited potent anti-tumor activity and selective depletion of tumor-associated Tregs without affecting peripheral Tregs. In the GLP toxicity study, the CTLA-4×TIGIT BsAb exhibited a more favorable safety profile than CTLA-4 mAbs such as ipilimumab and tremelimumab. Conclusion: Our preclinical study thoroughly evaluated the in vitro and in vivo activity of the CTLA-4×TIGIT BsAb and demonstrated its mechanism of action in targeting tumor-associated Tregs, which confirms that the specificity towards tumor-associated Treg cells preserves efficient anti-tumor activity while enhancing the safety profile of CTLA-4 targeting therapy. The GLP toxicity study demonstrated that CTLA-4×TIGIT BsAb is expected to reduce peripheral adverse reactions and improve tolerance. The promising preclinical data support its advancing into clinical testing, and an Investigational New Drug (IND) application to NMPA has been submitted in Dec 2024. Citation Format: Hong Yan, Luyao Bao, Chenglong Liu, Simeng Chen, Wei Zhang, Xing Sun, Wenjing Cheng, Zeyun Xue, Wei Wang, Jimin Yuan, Cheng Liao. A first-in-class CTLA-4×TIGIT BsAb selectively targets tumor-associated Treg cells to improve the safety profile of CTLA-4 targeting therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB368.
APA, Harvard, Vancouver, ISO, and other styles
10

Zhang, Yu, Xiang Wang, and Xiuping Zhou. "Functions of Yes-association protein (YAP) in cancer progression and anticancer therapy resistance." Brain Science Advances 8, no. 1 (2022): 1–18. http://dx.doi.org/10.26599/bsa.2022.9050008.

Full text
Abstract:
The Hippo pathway, a highly conserved kinase cascade, regulates cell proliferation, apoptosis, organ size, and tissue homeostasis. Dysregulation of this pathway reportedly plays an important role in the progression of various human cancers. Yes-association protein (YAP), the Hippo pathway’s core effector, is considered a marker for cancer therapy and patient prognosis. In addition, studies have indicated that YAP is involved in promoting anticancer drug resistance. This review summarizes current knowledge on YAP’s role in cancer progression, anticancer drug resistance, and advances in the development of YAP-targeting drugs. A thorough understanding of the complex interactions among molecular, cellular, and environmental factors concerning YAP function in cancer progression may provide new insight into the underlying mechanism of anticancer drug resistance. It might lead to improved prognosis through novel combined therapies.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Bsam yas"

1

Kendrīya-Tibbatī-Ucca-Śikṣā-Saṃsthānam, ed. Bsam-yas brtsod pa. Wā-ṇa dbus Bod kyi ches mthoʼi gtsug lag slob gñer khaṅ, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chungam. Kkamallassilla ŭi susŭp ch'aje yŏn'gu: Ssamye (bSam yas) ŭi nonjaeng yŏn'gu. Pulgyo Sidaesa, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Blo-bzang-dar-rgyas. Bsam-yas-chos-rtsod lta grub kyi dpyad pa byis pa dgod paʼi rdzun rkong. Krung-goʹi Bod-rig-pa Dpe-skrun Khang, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Skyabs rje bla ma karma stobs rgyal rin po che. Chos ʼkhor dpal gyi bsam yas mchod rten rnams kyi dkar chag kun gsal me long zhes bya ba bzhugs so. Bod ljongs mi dmangs dpe skrun khang, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ṅag-dbaṅ-rgyal-po, Legs-bśad-thogs-med та Zla-ba-rgyal-mtshan, ред. Sa yi steṅ na ʼgran zla daṅ bral ba dpal Bsam-yas mi ʼgyur lhun gyi grub paʼi gtsug lag khaṅ gi dkar chag. Mi rigs dpe skrun khaṅ, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tshe-ring-zla-ba, Shar-gzhon. Yar-ʼbrog Bsam-sdings-dgon gyi byung ba brjod pa yid kyi shing rta zhes bya ba. Krung-goʼi Bod-rig-pa dpe-skrun Khang, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Blo-bzang-rgya-mtsho. Rgyal kun snying rje'i rang gzugs phyag na Padmo rgyal dbang Blo-bzang-rin-chen-tshangs-dbyangs-rgya-mtsho-dpal-bzang-boʼi zhal snga nas sku dngos kyis phyag ʼdebs mdzad paʼi bshad sgrub bstan paʼi ʼbyung gnas chos sde chen po Yar-lung-thos-bsam-dar-rgyas-gling gi lo rgyus dkar chag rab gsal me long zhes bya ba bzhugs so. [publisher not identified], 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bsod-nams-phun-tshogs. Dge baʼi bshes gnyen chen po Rje-btsun Bsod-nams-phun-tshogs mchog gi rang rnam dpag bsam ljon shing ʼgro baʼi gtan bdeʼi ʼbyung gnas yal ʼdab bco brgyad pa zhes bya ba bzhugs so. Bod-kyi ʼGro-ba Miʼi-thob-thang dang Mang-gtso-ʼphel-rgyas Lte-gnas-khang, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bsam-yas dkar chag. Kan-suʼu mi rigs dpe skrun khaṅ, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

ILL - Sources for a history of the bSam yas debate. 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bsam yas"

1

van Roode, Mark, and Arun K. Bhattacharya. "Durability of Oxide/Oxide CMCs in Gas Turbine Combustors." In ASME Turbo Expo 2012: Turbine Technical Conference and Exposition. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/gt2012-68974.

Full text
Abstract:
An integrated creep rupture strength degradation and water vapor degradation model for gas turbine oxide-based CMC (Ceramic Matrix Composite) combustor liners was expanded with heat transfer computations to establish maximum TRIT (Turbine Rotor Inlet Temperature) for gas turbines with 10:1 pressure ratio. Recession rates and average CMC operating temperatures were calculated for an existing baseline N720/A (N720/Al2O3) CMC combustor liner system, with and without protective Al2O3 FGI (Friable Graded Insulation) for 30,000-h liner service life. The potential for increasing TRIT by YAG (Y3Al5O12) substitution for the fiber, matrix and FGI constituents of the CMC system was explored, because of the known superior creep and water vapor degradation resistance of YAG compared to Al2O3. It was predicted that uncoated N720/A can be used as a combustor liner material up to a TRIT of ∼1200°C, offering no TRIT advantage over a conventional metal + TBC (Thermal Barrier Coating) combustor liner. A similar conclusion was previously reached for a SiC/SiC CMC liner with BSAS-type EBC (Barium Strontium Aluminum Silicate Environmental Barrier Coating). The existing N720/A + Al2O3 FGI combustor liner system can be used at a maximum TRIT of ∼1350°C, a TRIT increase over metal + TBC and uncoated N720/A of ∼150°C. Replacing the Al2O3 with YAG is predicted to increase the maximum allowable TRIT. Substitution of the fiber or matrix in N720/A increases TRIT by ∼100°C. A YAG FGI improves the TRIT of the 720/A + Al2O3 FGI by ∼50°C, enabling a TRIT of ∼1400°C, similar to that predicted for SiC/SiC CMCs with protective rare earth monosilicate EBCs.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Bsam yas' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography